Takeda Pharma Files 6-K, Confirms 20-F Reporting
Ticker: TKPHF · Form: 6-K · Filed: Apr 1, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Apr 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, routine-report
TL;DR
Takeda filed a 6-K, confirming it's a foreign private issuer using Form 20-F. No new info.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on April 1, 2025, reporting its status as a foreign private issuer. The filing indicates that Takeda will file its annual reports under Form 20-F. No specific financial transactions or operational updates were detailed in this particular filing.
Why It Matters
This filing is a routine procedural update for foreign private issuers, confirming their reporting framework with the SEC and does not contain new operational or financial information.
Risk Assessment
Risk Level: low — This is a routine administrative filing by Takeda, providing no new material information that would impact its stock price or business operations.
Key Players & Entities
- TAKEDA PHARMACEUTICAL CO LTD (company) — Filer of the 6-K report
- 001-38757 (other) — SEC File Number for Takeda
- 20250401 (date) — Filing date and period of report
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to furnish information that the registrant makes or is required to make public pursuant to the laws of its home country, or is required to file with or submit to any stock exchange on which it has securities listed, or is made or is required to be made public by the registrant.
Which form does Takeda Pharmaceutical Company Limited use for its annual reports?
Takeda Pharmaceutical Company Limited indicates it files its annual reports under cover of Form 20-F.
What is Takeda's principal executive office address?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
What is the SEC file number for Takeda Pharmaceutical Company Limited?
The SEC file number for Takeda Pharmaceutical Company Limited is 001-38757.
Does this 6-K filing contain specific financial results or operational updates?
No, this Form 6-K filing is a routine report for the month of April 2025 and primarily serves to confirm Takeda's status as a foreign private issuer and its reporting obligations, rather than disclosing new financial or operational information.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 1, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).